Curated News
By: NewsRamp Editorial Staff
November 19, 2025
Neurothera & Clearmind File Patent for Novel Depression Therapy
TLDR
- Neurothera Labs' new patent filing for MEAI and PEA combination therapy could provide a competitive edge in the $280 million depression treatment market.
- The therapy combines MEAI and N-Acylethanolamines like PEA, targeting depression through preclinical data showing efficacy while preserving natural reward pathways.
- This innovative depression treatment could improve quality of life for millions worldwide affected by major depressive disorder, a leading cause of disability.
- Neurothera Labs' 13th patent filing combines MEAI with PEA, expanding their portfolio for treating depression, addiction, and obesity through novel drug combinations.
Impact - Why it Matters
This development represents a potential breakthrough in treating depression, a condition affecting over 280 million people worldwide according to the World Health Organization. Current depression treatments often come with significant side effects and limited efficacy for many patients. The combination therapy of MEAI and PEA offers a novel approach that preclinical data suggests could mitigate addictive behaviors while preserving natural reward pathways, potentially providing a safer, more effective alternative. Given depression's status as a leading cause of global disability and the limited innovation in antidepressant treatments over recent decades, this patent filing signals important progress toward addressing a massive unmet medical need that impacts individuals, families, and healthcare systems worldwide.
Summary
Neurothera Labs Inc., a clinical-stage biotech company and wholly-owned subsidiary of SciSparc Ltd., has announced a significant breakthrough in mental health treatment through its collaboration with Clearmind Medicine Inc. The partnership has resulted in the filing of an Israeli patent application for an innovative combination therapy using 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, specifically Palmitoylethanolamide (PEA), targeting depression treatment. This development comes at a critical time when the World Health Organization reports that major depressive disorder affects more than 280 million people globally, making it one of the leading causes of disability worldwide with limited innovative treatment options currently available.
The patent filing represents the latest achievement in the ongoing collaboration between Neurothera and Clearmind Medicine, further expanding their joint intellectual property portfolio that now includes 13 filed patents. These patents focus on MEAI and N-Acylethanolamines combinations for various conditions including alcohol use disorder, cocaine addiction, obesity and weight loss, and now depression. The therapeutic approach is supported by compelling preclinical data demonstrating MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways, suggesting a potentially safer alternative to existing treatments. The companies are advancing MEAI-based treatments toward clinical development through their innovative NEWMEDIAWIRE platform.
As a clinical-stage pharmaceutical company, Neurothera Labs focuses on developing novel therapeutics for central nervous system disorders and other underserved health conditions through strategic collaborations and innovative drug combinations. The company's mission to address some of the world's most challenging mental health conditions aligns with growing global recognition of mental health as a critical public health priority. Investors and stakeholders can access additional information through regulatory filings available at www.sedarplus.ca, while the broader medical community awaits further developments in this promising therapeutic approach that could revolutionize depression treatment.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Neurothera & Clearmind File Patent for Novel Depression Therapy
